Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
Organon & Co OGN
$13.55
▲ +0.00%
(+$0.00)
📅 Earnings This Week
Open
$13.55
Prev Close
$13.55
Day Range
$13.54 – $13.57
52W Range
$5.69 – $13.60
Market Cap
$3.56B
P/E (TTM)
14.46
Beta
1.52
Div Yield
0.59%
EPS (TTM)
$0.94
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2021-05-14 |
| Shares Out. | 262,610,000 |
| Website | organon.com/ ↗ |
| Phone | 13026587581 |
| Employees | 10,000 |
| Revenue | $1.46B |
| Gross Profit | $783.0M |
| Net Income | $146.0M |
| Free Cash Flow | $683.0M |
| Total Assets | $13.00B |
| Total Liabilities | $12.09B |
| Equity | $903.0M |
About Organon & Co
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Organon & Co is a publicly traded company under the ticker symbol OGN on the NEW YORK STOCK EXCHANGE, INC., operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)